PAS
GPCR icon

Point72 Asia (Singapore)’s Structure Therapeutics GPCR Stock Holding History

Point72 Asia (Singapore)’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$28 Hold
1
– – ﹤0.01% 844
2025
Q2 		$21 Hold
1
– – ﹤0.01% 844
2025
Q1 		$17 Hold
1
– – ﹤0.01% 822
2024
Q4 		$23 Buy
+1
New +$35 ﹤0.01% 830

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Asia (Singapore)'s GPCR Position: Q3 2025 in Review

Point72 Asia (Singapore) held its Structure Therapeutics (GPCR) position steady in Q3 2025 at 1 share worth $28. The position accounts for ﹤0.01% of the portfolio, ranked #844.

Point72 Asia (Singapore) first reported a position in GPCR in Q4 2024 and has held it in 4 quarters since. 156 funds tracked by Wall St. Rank hold GPCR as of Q3 2025.

  • Point72 Asia (Singapore) held 1 share of Structure Therapeutics worth $28 as of Q3 2025.
  • Point72 Asia (Singapore) left its Structure Therapeutics share count unchanged in Q3 2025.
  • Structure Therapeutics made up ﹤0.01% of Point72 Asia (Singapore)'s portfolio in Q3 2025, its #844 holding.
  • Point72 Asia (Singapore) first reported a position in Structure Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 156 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.